15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 预防乙型肝炎围产期传播需要考虑妊娠期抗病毒治疗。 ...
查看: 580|回复: 1
go

预防乙型肝炎围产期传播需要考虑妊娠期抗病毒治疗。 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2018-8-4 16:35 |只看该作者 |倒序浏览 |打印
Hepatology. 2018 Aug 2. doi: 10.1002/hep.30137. [Epub ahead of print]
Preventing Perinatal Transmission of Hepatitis B Necessitates Consideration of Antiviral Treatment in Pregnancy.
Terrault N1, Brown R Jr2, Lok A3, Wong J4, Chang KM5, Jonas M6, McMahon B7.
Author information

1
    University of California San Francisco, UCSF, Department of Medicine.
2
    Columbia University, Medicine.
3
    University of Michigan.
4
    Tufts Medical Center, Division of Clinical Decision Making Hwang, Jessica.
5
    Philadelphia VAMC & University of Pennsylvania, Medical Research Bzowej, Natalie.
6
    Children's Hospital Boson, Division of Gastroenterology, Hepatology and Nutrition.
7
    Alaska Native Tribal Health Consortium, Liver Disease and Hepatitis.

Abstract

Prevention of mother-to-child transmission of hepatitis B virus (HBV) is a major component of the HBV elimination efforts in every country. We thank Drs. Mubarak and Ferstenberg for highlighting the AASLD2018 Updated Hepatitis B Guidance on prevention of mother-to-child transmission 1 and conclusions from a recently published randomized clinical trial by Jourdain et al. of tenofovir disoproxil fumarate (TDF) versus placebo in pregnancy2 . In the Jourdain et al. study, TDF was not associated with a statistically significant reduction in perinatal transmission of HBV, but the 2% rate of perinatal transmission with placebo was much lower than the expected 12%, leaving the study underpowered to detect a statistically significant difference. Notably, no infants became infected in the TDF treated group, similar to another randomized trial comparing third trimester TDF to placebo This article is protected by copyright. All rights reserved.

PMID:
    30070717
DOI:
    10.1002/hep.30137

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2018-8-4 16:35 |只看该作者
肝病。 2018年8月2日doi:10.1002 / hep.30137。 [提前打印]
预防乙型肝炎围产期传播需要考虑妊娠期抗病毒治疗。
Terrault N1,Brown R Jr2,Lok A3,Wong J4,Chang KM5,Jonas M6,McMahon B7。
作者信息

1
    加州大学旧金山分校,加州大学旧金山分校,医学系。
2
    哥伦比亚大学医学。
3
    密歇根大学。
4
    塔夫茨医疗中心,临床决策部黄,杰西卡。

    费城VAMC和宾夕法尼亚大学,医学研究Bzowej,娜塔莉。
6
    儿童医院Boson,消化内科,肝脏病学和营养学。
7
    阿拉斯加原住民部落健康联盟,肝病和肝炎。

抽象

预防母婴传播乙型肝炎病毒(HBV)是每个国家消除HBV的主要组成部分。我们感谢Drs。 Mubarak和Ferstenberg强调了AASLD2018最新的关于预防母婴传播的乙型肝炎指南1以及Jourdain等人最近发表的一项随机临床试验的结论。替诺福韦地索普西酯富马酸盐(TDF)与孕妇安慰剂的比较2。在Jourdain等人。研究显示,TDF与HBV围产期传播的统计学显着降低无关,但安慰剂围产期传播的2%率远低于预期的12%,因此研究不足以发现统计学上的显着差异。值得注意的是,没有婴儿在TDF治疗组中被感染,类似于另一项比较妊娠晚期TDF与安慰剂的随机试验本文受版权保护。版权所有。

结论:
    30070717
DOI:
    10.1002 / hep.30137
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-15 23:21 , Processed in 0.012729 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.